ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MOL Moleculin Biotech Inc

0.00
0.00 (0.00%)
- - Realtime Data
Share Name Share Symbol Market Type
Moleculin Biotech Inc TG:MOL Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

MOL Net Profit Declines in Second Quarter on Upstream Segment

13/08/2013 12:22am

Dow Jones News


Moleculin Biotech (TG:MOL)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Moleculin Biotech Charts.
 By Veronika Gulyas 
 

BUDAPEST--Hungary's market leading oil and gas company MOL Nyrt. (MGYOY, MOL.BU) suffered a decline in net profit in the second quarter versus the previous three-month period, the company's earnings report published Wednesday said. This was due mainly to lower crude oil prices and decreasing hydrocarbon production having hit the company's upstream operations, its most profitable segment.

MAIN FACTS:

-MOL's second-quarter net profit dropped to 20 billion forints ($88 million) versus HUF32.2 billion a quarter earlier.

-Profit rose significantly versus a year ago; second-quarter net income was HUF498 million in 2Q 2012.

-EBITDA, or earnings before interest, taxes, depreciation and amortization, came in at HUF112 billion, down 21% versus the previous quarter as seasonally stronger demand and sales in downstream was weakened by deteriorating external conditions such as lower motor fuel crack spreads and shrinking Brentā€Ural spread and unplanned shutdowns.

-MOL expects the quarterly loss to be offset in the longer term thanks to its Kurdistani operations in Iraq where it reached a milestone this quarter, Zsolt Hernadi, chief executive and chairman, said in the report.

-MOL finished trading down 0.9% or HUF150 at HUF16,300.

Write to Veronika Gulyas at veronika.gulyas@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


1 Year Moleculin Biotech Chart

1 Year Moleculin Biotech Chart

1 Month Moleculin Biotech Chart

1 Month Moleculin Biotech Chart

Your Recent History

Delayed Upgrade Clock